• M Groenink, A de Roos, B J Mulder, J A Spaan, and E E van der Wall.
• Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands.
• Am. J. Cardiol. 1998 Jul 15;82(2):203-8.

AbstractIt has been shown that beta-adrenergic blocking agents may reduce the rate of aortic root dilation and the development of aortic complications in patients with the Marfan syndrome. This may be due to beta-blocker-induced changes in aortic stiffness, of which distensibility and pulse wave velocity are in vivo measurable derivatives. We studied changes in distensibility at 4 levels of the aorta and pulse wave velocity along the entire aorta after 2 weeks of beta-blocker therapy in 6 Marfan syndrome patients and in 6 healthy volunteers, using magnetic resonance imaging (MRI) combined with brachial artery blood pressure measurements. In both groups, mean blood pressure decreased significantly (Marfan: 86 +/- 6 vs 78 +/- 5 mm Hg, p <0.05; control: 80 +/- 8 vs 73 +/- 3 mm Hg, p <0.05) (all data expressed as mean +/- 1 SD). At baseline, the Marfan syndrome patients exhibited decreased distensibility at the level of the ascending aorta (2 +/- 1 vs 6 +/- 2 10(-3)mm Hg(-1), p <0.01) and increased pulse wave velocity (6.2 +/- 0.4 vs 3.9 +/- 0.4 ms(-1), p <0.01) compared with control subjects. Only the Marfan syndrome patients had a significant increase in aortic distensibility at multiple levels and a significant decrease in pulse wave velocity after beta-blocker therapy (ascending aorta distensibility: 2 +/- 1 vs 4 +/- 1 10(-3)mm Hg(-1), p <0.05; abdominal aorta distensibility: 5 +/- 2 vs 8 +/- 3 10(-3)mm Hg(-1), p <0.05; pulse wave velocity: 6.2 +/- 0.4 vs 5.0 +/- 1.0 ms(-1), p <0.05). Thus, aortic stiffness in Marfan syndrome, together with mean blood pressure, is reduced by beta-blocker therapy, and MRI is well suited to detect these changes by measuring distensibility and pulse wave velocity.

29 keywords...

hide…